Research programme: bioavailability enhanced therapeutics - Samyang
Alternative Names: Aprepitant BA - Samyang; Candesartan BA - Samyang; Celecoxib BA - Samyang; Tacrolimus BA - SamyangLatest Information Update: 10 Apr 2025
At a glance
- Originator Samyang Biopharmaceuticals Corporation; Samyang Group
- Developer Samyang Biopharmaceuticals Corporation
- Class Benzimidazoles; Lactones; Macrolides; Morpholines; Pyrazoles; Small molecules; Sulfonamides; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcineurin inhibitors; Cyclo-oxygenase 2 inhibitors; Cytokine inhibitors; Immunosuppressants; Neurokinin 1 receptor antagonists; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Hypertension; Nausea and vomiting; Rheumatoid arthritis; Transplant rejection
Most Recent Events
- 10 Apr 2025 Discontinued - Preclinical for Hypertension in South Korea (PO)
- 10 Apr 2025 Discontinued - Preclinical for Nausea and vomiting in South Korea (PO)
- 10 Apr 2025 Discontinued - Preclinical for Rheumatoid arthritis in South Korea (PO)